The estimated 3-year inappropriate shock rate was 13.1% most due to oversensing of cardiac sig- nals, and mortality was 4.7%. Device-related complications occurred in 11.1% of patients. An ongoing trial will compare the effect of the sub- cutaneous implantable cardioverter-defibrillator with that of the transvenous ICD on the out- comes of inappropriate shocks, complications, shock efficacy, and mortality.S11.1-13 3. The subcutaneous implantable cardioverter- defibrillator is incapable of bradycardia pac- ing, biventricular pacing, or antitachycardia pacing. Therefore, patients who need any of these types of pacing from an ICD should not be offered a subcutaneous implantable cardioverter- Some clinical scenarios may come up in which a transvenous pacemaker for bradycardia pacing in a patient with a subcutane- ous implantable cardioverter-defibrillator which is needed; this can be performed as long as the pacing is not unipolar. Leadless pacing devices for patients who require bradycardia pacing will be evaluated with the subcutaneous implantable cardioverter-defibrillator in the near future. 11.2. Wearable Cardioverter-Defibrillator Recommendations for Wearable Cardioverter-Defibrillator References that support the recommendations are summarized in Online Data Supplement 56. 